Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rivastigmine
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Luye Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through the agreement, the company grants Exeltis exclusive rights to commercialize the Rivastigmine MD (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.
Brand Name : Rivastigmine MD
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 31, 2022
Lead Product(s) : Rivastigmine
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Luye Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Secnidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Details : This partnership will expand the reach of SOLOSEC®, allowing more Healthcare Providers to be aware of the benefits of SOLOSEC®, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis.
Brand Name : Solosec
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 27, 2022
Lead Product(s) : Secnidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Rizatriptan Benzoate
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : IntelGenx
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the current agreement, IntelGenx will grant Exeltis an exclusive license to manufacture and commercialize RIZAPORT® in the EU.
Brand Name : Rizaport
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 27, 2020
Lead Product(s) : Rizatriptan Benzoate
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : IntelGenx
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?